NASDAQ:HBIO
Harvard Bioscience Inc.
Harvard Bioscience Inc.'s revenue fell 8.1% in fiscal 2025 to $86.5M while operating margin fell to −56.1%, its lowest in 10 years. Free cash flow was $5.5M, 6.3% of revenue, and the diluted share count rose 2.0%.Summary generated from Harvard Bioscience Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$86.5M
Revenue growth−8.1%
Revenue, 5-yr CAGR−3.3%
Gross margin57.7%
Operating margin−56.1%
Net margin−65.5%
ROIC−56.0%
Return on equity−147.1%
Debt / equity2.61
Free cash flow$5.5M
FCF margin6.3%
Share count change+2.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 119 | 113 | 112 | 94 | 87 |
| Operating income | 2 | −7 | 2 | −6 | −49 |
| Net income | −0 | −10 | −3 | −12 | −57 |
| Free cash flow | 0 | −0 | 12 | −1 | 5 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KRegulation FD disclosure
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Jun 12, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KDirector or officer change
Jun 2, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026 - 8-KRegulation FD disclosure
May 12, 2026